Can we still use our Primary Engineering Control if it fails its testing/certification ?

Any examples are for illustrative purposes only.

It is up to the organization to determine whether or not the compounding space is acceptable to continue producing sterile compounded medication products.  Factors should include the pathogenicity of the organism grown in the positive growth viable sample; complexity level of the compounded product; any known/potential associated hospital acquired infections; and guidance from the infection control practitioner.